14.06.2012 - Italian neuroscience specialist Newron Pharmaceuticals S.p.A. acquires the Stockholm-based Neuronova AB in a deal worth €15.4m
Bresso/Stockholm – The transaction will add two new Phase II compounds from NeuroNova to Newron’s CNS portfolio. sNN0031 is a novel drug candidate for the treatment of moderate to severe stage Parkinson’s disease (PD) that is designed to act on neural stem and progenitor cells in the brain. In a Phase I/II trial in patients with PD, the active ingredient platelet-derived growth factor BB demonstrated preliminary beneficial effects on biochemical markers of the degenerating dopamine system in PD patients. The second compound, sNN0029 with the active ingredient vascular endothelial growth factor, is intended for the treatment of amyotrophic lateral sclerosis (ALS) and is currently evaluated in a Phase I/II trial.
At the transaction close, Newron will benefit by cash and commitments of up to €16m. These funds are sufficient to provide for a Phase II study in PD as well as the ongoing Phase I/II study in ALS, in addition to the related corporate operations. The biggest investors in Neuronova, Investor and Healthcap, will also take a stake in Newron. Both will send a representative to the Milan-based company’s board of directors. At closing of the deal, the Neuronova shareholders will represent a holding of 33% in Newron’s share capital. For them, the transaction is a bid on the positive development of NeuroNova’s compounds. “We value Newron’s expertise in taking compounds from clinical stages to regulatory filing, and support the concept of building a European CNS player that could benefit both patients and our stakeholders”, stated Jakob Lindberg from Investor. “It is the logical next step to NeuroNova to combine our advanced pipeline and know-how, originally stemming from research at Karolinska Institute and developed by our team in the recent years, with a larger player in the CNS field”, added Ulf Ljungberg, President and CEO of NeuroNova, stating that the combined product portfolio represents “a strong platform on which to build the critical mass this industry is looking for.”
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more